| INTRODUCTION
Intimal arteritis, also called "v-lesion" according to the Banff classification of renal allograft pathology, is characterized by an infiltration of mononuclear cells beneath the arterial endothelium. It is considered pathognomonic of active rejection, 1 which can be either T cellmediated or antibody-mediated, and severely worsens graft outcome.
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Isolated v-lesion (IvL) is defined as intimal arteritis that occurs with
minimal concurrent tubulointerstitial inflammation, that is, the diagnosis falls below the threshold for grade IA T cell-mediated rejection (TCMR). 3 IvL represents an unusual situation with unclear clinical and prognostic significance for which the Banff classification is problematic. 4 Arterial involvement is sufficient to classify IvL as type II or III acute TCMR if pathologists rigorously comply with the instructions of the "historical" Banff scheme. 5, 6 Recent data highlighted that intimal arteritis could be considered as antibody-mediated rejection (ABMR) 2 and, subsequently, the 2013 update of the Banff classification introduced v > 0 as a morphological change that is consistent with ABMR when occurring in conjunction with "evidence of antibody interaction with endothelium" in a donor-specific antibody (DSA)-positive patient. 7 However, the role of the humoral immune response in the pathophysiology of IvL remains unclear, as the incidence of DSAs has not been systematically addressed in previous studies focusing on IvL. 6, [8] [9] [10] [11] Therefore, this multicentric study was conducted to thoroughly characterize the clinicopathologic phenotype of patients with IvL. We placed a particular emphasis on the relationship between IvL and humoral rejection. Therefore, we assessed (1) the DSA status of patients with IvL at the time of biopsy and after 1 year, studied (2) the histological feature of subsequent kidney biopsies, and compared (3) the kidney graft survival of patients with IvL to that with ABMR patients with arteritis.
| MATERIAL AND METHODS
| Study population
Computerized records from the pathology departments of four French Biopsies with the usual forms of TCMR or ABMR were excluded in accordance with inclusion criteria. Also excluded were patients with a history of biopsy-proven rejection in the previous 3 months.
Clinical, immunological, and biological records were retrospectively reviewed for all patients. The main outcome was kidney allograft loss, determined by the return to dialysis.
antibody-mediated rejection with arteritis. In conclusion, IvL is not primarily antibodymediated and may show a favorable evolution. T A B L E 1 Population baseline characteristics
Recipient characteristics n = 33
Recipient age (year, mean ± SD) 55 ± 11
Recipient gender (male, n, %) 23 (69.7)
Cause of end-stage renal disease, n (%) 
| Renal allograft histology
Renal Isolated V lesions were defined by any v-lesion (v1, v2, or v3) with minimal-to-no interstitial inflammation (i ≤ 1 with any t-score), minimalto-no microvascular inflammation (g + ptc ≤ 1), and negative C4d staining. DSAs at 1 year after IvL were also evaluated in all patients with a functioning graft at 1 year and available serum.
| Definitions of v-lesions and isolated v-lesions
| Donor-specific antibodies
| Immunosuppression
Basiliximab (Simulect, Novartis Pharma AG, Basel, Switzerland) or rabbit ATG (Thymoglobuline, Sanofi, France) were used for induction therapy. The immunosuppression was based on conventional tripledrug immunosuppressive regimen consisting of calcineurin inhibitors, mycophenolic acid, and prednisone. Patients judged as having T cellmediated IvL were given methylprednisolone pulses (500 mg/day for 3 days). IvL cases judged as antibody-mediated were given methylprednisolone pulses (500 mg/day for 3 days) and intravenous immunoglobulins and/or plasmapheresis and/or rituximab.
| Statistics
Continuous variables are reported as the median, min, max, and interquartile range or as the mean and standard deviation (SD). We Statistical analyses were performed with GraphPad PRISM 5 software.
| RESULTS
| Clinicopathological phenotype of IvL
| Baseline clinical characteristics
Among the 11 076 kidney transplant biopsies performed in the 4 centers during the 10-year study period, 33 IvL cases were identified (0.3%). The incidence of IvL in for-cause biopsies performed in the first 3 months (n = 2436), in 3-month protocol biopsies (n = 3323), and in biopsies performed after 3 months (n = 5317) was 0.7%, 0.24%, and 0.15%, respectively.
The demographic data and baseline characteristics of the population are summarized in Table 1 and detailed in Induction therapy included basiliximab in 24 cases (72.7%) and thymoglobulin in 9 cases (27.3%).
| Donor-specific antibodies at the time of index biopsy
Five recipients (15.2%) had DSAs at the time of biopsy. Three were preformed DSAs (2 class I and 1 class II anti-HLA DSAs) and 2 developed de novo class II DSAs (anti-DQ DSAs). Immunodominant DSAs (iDSAs) were class II DSA in 3 patients (9%). Median MFI of the iDSA was 1208 and ranged from 700 to 2691 (Table 2) .
| Characteristics of index biopsies
Kidney biopsies were clinically indicated in most of cases (n = 22, 66.7%); 11 were protocol biopsies (33.3%) (8 of which were performed at 3 months and 3 of which were performed at 1-year posttransplantation). Indication for for-cause biopsies were mainly graft dysfunction, either increased creatinine serum (n = 13, 39.4%) or DGF in the early posttransplantation period (n = 9, 27.3%) ( Table 2 and Table 3 ).
Overall, kidney biopsies were performed mainly in the early posttransplantation period after a median time of 27 days. All biopsies (except one delayed 1-year protocol biopsy at day 407) were performed before or at 1-year posttransplantation. At the time of biopsy, the mean serum creatinine level was 335 ± 327 μmol/L, and 2 patients were on hemodialysis for DGF.
Histological findings of the index kidney biopsies are shown in Table 2 and detailed in Table 3 as well as illustrated in Figure 1 
| Clinical and pathological follow-up of IvL
| Characteristics of subsequent biopsies
Twenty-one patients (63.6%) were treated for rejection whereas onethird of patients (n = 12, 36.4%) were left untreated. Thirty-one patients (93.9%) had a subsequent biopsy that was performed after a median time of 85 days (51-181) after the index biopsy (see Table 4 for details and Table S1 for summary). Subsequent biopsies were protocol biopsies in most cases (n = 29, 93.5%). Two additional biopsies were done for other cause (proteinuria and DSAs). Subsequent biopsies showed no rejection (n = 19) or borderline lesions (n = 2) in 21 patients (67.7%), who corresponded to 7/10 patients of the untreated group and 14/21 patients of the treated group (Figure 2 ). IvL persisted in 6 patients (19.4%; 2 in the untreated group and 4 in the treated group). TCMR was observed in 3 patients (9.7%; 1 untreated had a TCMR grade IIA and 2 treated patients had a TCMR grade IA and IIA).
Mixed ABMR-TCMR rejection was detected in another treated case (patient 9).
Chronic histological changes did not significantly increase between paired index and subsequent biopsies as shown by the delta cv (+0.07, P = NS) and the delta interstitial fibrosis and tubular atrophy (IF/TA) scores (+0.46, P = NS).
| Clinical outcome
Median follow-up after the index biopsy was 66 (40-90) months.
One-year DSAs were evaluated in 30 patients (Table 4) Three patients (9%) lost their graft (due to rejection in 2 cases [patients 2 and 25] and infarction in patient 24 due to renal arterial thrombosis while rejection persisted on subsequent biopsies) at 2.0, 13.3, and 22.2 months after the index biopsy.
| Graft survival
Overall graft survival was 93.8% and 90.4% at 1 year and 5 years after index biopsy, respectively. Overall mean serum creatinine levels at 3 months, 1 year, and 5 years after the index biopsy were 138 ± 49, 132 ± 40, and 129 ± 34 μmol/L, respectively.
Three patients (9%) died with a functioning graft during the follow-up. Cause of death was cardiovascular in 1 patient and malignancies in 2 patients. Among these 5 DSA-positive patients, only 1 patient further developed severe ABMR, and another patient lost his graft from rejection after 2 months. We then compared the kidney graft survival of our true in early biopsies, as 9 of the 12 biopsies performed in the first year posttransplantation showed no molecular signature of rejection.
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These findings could suggest that mechanisms different from rejection, that is, endothelial injury related to ischemia-reperfusion, may operate in some cases of IvL. 3 Of interest, all cases from the present series occurred within the first year posttransplantation and mainly in the early posttransplantation period, after a median time of 27 days, with a decreasing incidence over time. Indeed, numerous studies using murine ischemia reperfusion injury (IRI) models have demonstrated that both the innate and adaptive immune systems mediate renal injury after IRI. 17, 18 Notably, IRI increases vascular permeability and facilitates extravasation of leukocytes by interrupting the integrity of renal vascular endothelium. Although a causal relationship between IRI and IvL cannot be ascertained in our study, it is of note that the majority of donors were deceased donors and that DGF occurred in a high proportion of patients (39%).
Limitations of the study include its retrospective design with the noncontrolled nature of the treatment, the relatively small number of cases, which can be explained by the rarity of IvL, and the heterogeneity of our cohort. However, the heterogeneity of our cohort depicts IvL in a real-life setting, where IvL is rare and found in indication but also in protocol biopsies, with heterogeneous interpretation and treatment. In the present study, we used a threshold of more than 
| CONCLUSION
Our results focusing on the relationship of IvL and humoral rejection suggest that IvL occurring in the first year posttransplantation is rarely associated with DSA and that very few patients further develop ABMR. IvL has a good prognosis but should prompt close clinical and histological follow-up because of its potential association with rejection. Further studies are needed to delineate the pathogenesis and prognosis of this rare and heterogeneous entity.
